RB1 and cancer: Since RB1 function can clearly be compromised by multiple events in addition to direct genetic loss in human cancers (e.g., HPV-E7 or CDK4/6 activity), we focused on developing a transcriptional tool to evaluate RB activity based on transcription that could be broadly deployed across tumors.